Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$0$0$0$0$0
$5.23M+14.2%$6.06M+52.3%$4.97M+68.6%$4.93M+74.5%$4.58M+27.7%
$2.3M+13.9%$1.76M+125%$4.95M+522%$2.02M+98.3%
$23.47K+67.0%$22.54K+27.8%$21.29K-26.9%$13.37K-62.5%$14.06K-59.0%
$419.04K+281%
$7.53M+7.3%$8.17M+43.5%$6.73M+80.4%$9.88M+173%$7.02M+52.4%
$7.53M+7.3%$8.17M+43.5%$6.73M+80.4%$9.88M+173%$7.02M+52.4%
$27.97K$608.75K+16.4%$16.53K-99.2%
$21.28K-78.7%$609-99.6%$6.06K-95.4%$29.47K-49.2%$100.1K+1,407%
-$6.7K-102%$1.41M-63.4%-$372.85K-877%$352.12K+121%$352.65K+377%
-$7.54M-13.1%-$6.76M-12.8%-$7.1M-27.3%-$9.52M-80.9%-$6.66M-37.6%
$2.09K0.0%$2.09K$2.09K+4.5%$2.09K$2.09K+4.5%
-$0.13+13.3%-$0.13-$0.14+74.1%-$0.21+51.2%-$0.15+62.5%
-$0.13+13.3%-$0.13-$0.14+74.1%-$0.21+51.2%-$0.15+62.5%
60M+38.3%47.9M+157%50.7M+316%44.6M+266%43.4M+257%
60M+38.3%47.9M+157%50.7M+316%44.6M+266%43.4M+257%
$28.39K$28.39K$28.39K$28.39K
$0-100%$138.3K+860%$322.66K+2,140%$252.55K+1,653%
$46.25K$46.25K$46.25K$46.25K
$452.01K+1.5%$0-100%-$6.21M-486%$1.86M$445.54K-35.6%
$21.28K-78.7%$609-99.6%$6.06K-95.4%$29.47K-49.2%$100.1K+1,407%
$7.14M+1,403%$6.51M+168%$5.27M-66.4%$8.7M+24.0%-$547.88K-112%
-$48.85K+95.8%-$27.85K+96.6%$0+100%-$156.46K-848%-$1.15M-5,655%
-$4.41M+6.9%-$5.56M-114%-$11.09M-487%-$6.25M-97.3%-$4.74M-23.6%
$185.02K
-$6.7K-102%$1.41M+569%-$372.85K+79.8%$352.12K+121%$352.65K+249%
$2.09K0.0%$2.09K$2.09K$2.09K$2.09K-65.2%
$2.8M+96.3%$2.15M+99.0%$1.45M+437%$1.41M+411%$1.42M+326%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is TuHURA Biosciences, Inc. profitable?
TuHURA Biosciences, Inc. is not currently profitable: it reported a net loss of $30.9M over the trailing twelve months.
What is TuHURA Biosciences, Inc.'s earnings per share?
TuHURA Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.61.
Where does TuHURA Biosciences, Inc.'s income statement data come from?
Every line is extracted from TuHURA Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.